The Next Generation of RMP1-14: Enhanced Efficacy, Lower Doses, Clearer Results

Unleash the Power of LALAPG Technology

Key Benefits

Potential for clearer results in early-stage tumor growth studies
Opportunity to explore the impact of lower endotoxin levels
Supports the 3Rs principle in animal research
Viable alternative to BE0146

Tumor Growth Inhibition: Tumor Volume Over Time

ICH1182LALAPG, our murinised LALAPG version of the gold-standard RMP1-14 antibody, demonstrates superior tumor growth inhibition compared to the traditional RMP1-14 (BE0146).

Maintain Research Integrity with Comparable Safety Profile

ICH1182LALAPG shows a similar impact on body weight as traditional RMP1-14, ensuring continuity in your experimental protocols.

Why Switch to ICH1182LALAPG?

01

Optimize Your Research
Achieve more pronounced effects with the same or lower doses.

02

Enhance Sensitivity
Better differentiate the impact of your novel therapeutics from baseline anti-PD-1 effects.

03

Streamline Experiments
Potential for shorter study durations or reduced animal numbers.

04

Stay Cutting-Edge
Align your research with the latest advancements in antibody engineering.

Elevate Your Immuno-Oncology Studies

By incorporating ICH1182LALAPG into your research, you can:

Gain a clearer understanding of your experimental treatments’ efficacy.
Potentially reduce time and resources needed for conclusive results.
Set a new gold standard for anti-PD-1 controls in your lab.

Expert Opinion

“ICH1182LALAPG represents a significant leap forward in anti-PD-1 antibodies for preclinical research. Its enhanced tumor growth inhibition properties offer researchers a more powerful tool to evaluate novel cancer therapies.”

Dr. Elaine Zhang, Lead Researcher

Ready to Upgrade Your Research?

We’re looking to switch as many researchers as possible from the standard RMP1-14 Rat IgG2a hybridoma to the murinised LALAPG version.

Contact us today to receive a free sample to enable you to do your own internal comparison studies.